Literature DB >> 8099896

Expression of c-erbB-2 protein, neuron-specific enolase and DNA flow cytometry in locally advanced transitional cell carcinoma of the urinary bladder.

A Berner1, A B Jacobsen, S D Fosså, J M Nesland.   

Abstract

Expression of c-erbB-2 protein, neuron-specific enolase (NSE) and DNA ploidy was studied by immunohistochemistry and flow cytometry in formalin-fixed and paraffin-embedded specimens from 104 patients with locally advanced transitional cell carcinoma of the bladder. Positive membrane bound c-erbB-2 staining was found in 15% of the tumours, and 38% of the tumours were positive for NSE. Only one tumour stained positively for both NSE and c-erbB-2. Expression of c-erbB-2 protein and NSE was neither correlated to tumour stage nor to histopathological grade. The frequency of non-diploid tumours was 78% in 49 c-erbB-2/NSE negative tumours, 98% in 40 NSE positive tumours, and 100% in 16 c-erbB-2 positive tumours (P = 0.004). Whether the c-erbB-2 expression is a useful prognostic marker in addition to other conventional parameters, remains to be shown.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099896     DOI: 10.1111/j.1365-2559.1993.tb00131.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  2 in total

1.  Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinoma.

Authors:  Gonzague de Pinieux; Delphine Colin; Anne Vincent-Salomon; Jérôme Couturier; Delphine Amsellem-Ouazana; Philippe Beuzeboc; Annick Vieillefond
Journal:  Virchows Arch       Date:  2004-03-17       Impact factor: 4.064

2.  Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erbB-2 protein and HCG in operable muscle-invasive bladder cancer.

Authors:  S D Fosså; A A Berner; A B Jacobsen; H Waehre; B Kvarstein; T Urnes; P Ogreid; T E Johansen; J Silde; J M Nesland
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.